ncRNA name
hsa-miR-1269b
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
PTEN/PI3K/Akt
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Up
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
The miR-1269b/PTEN/PI3K/AKT mediated network might promote cisplatin resistance in NSCLC, and that miR-1269b can be a potential therapeutic target for chemoresistance in NSCLC patients.
Tissue resource
lung tissue samples were obtained from the resected lungs of non-small cell lung cancer patients
non-small cell lung cancer cell lines HA549
non-small cell lung cancer cell lines Sprostate cancer1
non-small cell lung cancer cell lines H1299
non-small cell lung cancer cell lines H358
non-small cell lung cancer cell lines PC9
non-small cell lung cancer cell lines A549/DDP
non-small cell lung cancer cell lines 16HBE
tumor samples with adjacent normal tissues
non-small cell lung cancer cell lines HA549
non-small cell lung cancer cell lines SPCA1
non-small cell lung cancer cell lines H1299
non-small cell lung cancer cell lines H358
non-small cell lung cancer cell lines PC9
non-small cell lung cancer cisplatin-resistant cell lines A549/DDP
non-small cell lung cancer cell lines 16HBE
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
the First Affiliated Hospital of Nanjing Medical University
the Shanghai Academy of Sciences
First Affiliated Hospital of Nanjing Medical University
Shanghai Academy of Sciences
Country
China
China
China
Continent
Asia
Asia
Asia